Cheryl M. Yemoto
Stanford University
17 Papers
243 Citations
Cheryl M. Yemoto is an academic researcher from Stanford University. The author has contributed to research in topics: Prostatectomy & Prostate-specific antigen. The author has an hindex of 15, co-authored 17 publications. Previous affiliations of Cheryl M. Yemoto include American Urological Association & University of Michigan.
Chat about Author
Papers
Assessment of morphometric measurements of prostate carcinoma volume
TL;DR: The authors have shown that the primary determinants of prostate carcinoma progression are tumor volume and the percent of the tumor comprised of Gleason Grade 4/5 cells.
96
Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and tnm subgroups
TL;DR: T1c cancers are similar to T2a cancers in tumor volume and percent Gleason grade 4/5, the primary determinants of therapeutic failure, and data suggest that the 4 clinical stages of T1c toT2c can serve as a valid basis for comparing different therapeutic strategies.
84
Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers
TL;DR: Cancer location in the peripheral zone and percent Gleason grade 4/5 are the most powerful predictors of biochemical failure in men whose cancer is 6 cc or greater and contained in the prostatic capsule.
59
Cell proliferation in dysplasia of the prostate: Analysis by PCNA immunostaining
TL;DR: Patterns of cell proliferation in the prostate were compared between benign epithelium and dysplasia and absolute cell densities (cells/mm) were determined and used to calculate growth fractions.
53
Modified Extrafascial Radical Retropubic Prostatectomy Technique Decreases Frequency of Positive Surgical Margins in T2 Cancers 3
TL;DR: Differences in surgical technique probably accounted for the significant decrease in +SM for those T2 cancers with volumes ≤2 cm3 which represents 36% of the T1c cancers in the series.
45